2098191-54-7 (rel-4-[(5aR,6S,7S,8R,8aS)-7-[(二甲胺)甲基]-6,7,8,8a-四氢-8,8a-二羟基-1,3-二甲氧基-6-苯基-5aH-环五[4,5]呋喃[3,2-c]吡啶-5a-基]-苯甲腈,Benzonitrile, 4-[(5aR,6S,7S,8R,8aS)-7-[(dimethylamino)methyl]-6,7,8,8a-tetrahydro-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-5aH-cyclopenta[4,5]furo[3,2-c]pyridin-5a-yl]-, rel-)

CAS号:
2098191-54-7
中文名称:
rel-4-[(5aR,6S,7S,8R,8aS)-7-[(二甲胺)甲基]-6,7,8,8a-四氢-8,8a-二羟基-1,3-二甲氧基-6-苯基-5aH-环五[4,5]呋喃[3,2-c]吡啶-5a-基]-苯甲腈
英文名称:
Benzonitrile, 4-[(5aR,6S,7S,8R,8aS)-7-[(dimethylamino)methyl]-6,7,8,8a-tetrahydro-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-5aH-cyclopenta[4,5]furo[3,2-c]pyridin-5a-yl]-, rel-
分子式:
C28H29N3O5
分子量:
487.5
简介:
reli -Zotatifin是Zotatifin的外消旋异构体,作为eIF4A抑制剂,活性小于Zotatifin。Zotatifin (eFT226) 是一种有效,选择性和耐受性良好的 eIF4A 抑制剂。Zotatifin 可促进 eIF4A 与 5'-UTRs 中具有识别基序的特定 mRNA 序列结合 (IC50=2 nM),并干扰 eIF4F 起始复合物的组装。

rel-4-[(5aR,6S,7S,8R,8aS)-7-[(二甲胺)甲基]-6,7,8,8a-四氢-8,8a-二羟基-1,3-二甲氧基-6-苯基-5aH-环五[4,5]呋喃[3,2-c]吡啶-5a-基]-苯甲腈(2098191-54-7)名称与标识符

名称

英文别名:
rel-Zotatifin;Benzonitrile, 4-[(5aR,6S,7S,8R,8aS)-7-[(dimethylamino)methyl]-6,7,8,8a-tetrahydro-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-5aH-cyclopenta[4,5]furo[3,2-c]pyridin-5a-yl]-, rel-;Zotatifin (eFT226);HY-112163;4-((5aR,6S,7S,8R,8aS)-7-((Dimethylamino)methyl)-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-6,7,8,8a-tetrahydro-5aH-cyclopenta[4,5]furo[3,2-c]pyridin-5a-yl)benzonitrile;NSC828584;4-[(2S,3R,4S,5S,6R)-4-[(dimethylamino)methyl]-2,3-dihydroxy-10,12-dimethoxy-5-phenyl-7-oxa-11-azatricyclo[6.4.0.02,6]dodeca-1(12),8,10-trien-6-yl]benzonitrile;Zotatifin [USAN];CS-0043584;EFT226;2EWN8Z05CN;4-{(5aR,6S,7S,8R,8aS)-7-[(Dimethylamino)methyl]-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-6,7,8,8a-tetrahydro-5aH-cyclopenta[4,5]furo[3,2-c]pyridin-5a-yl}benzonitrile;DTXSID001022536;D11837;WHO 10998;Zotatifin [USAN:INN];NSC-818001;ZOTATIFIN [WHO-DD];SCHEMBL18864788;4-[(2S,3R,4S,5S,6R)-4-[(dimethylamino)methyl]-2,3-dihydroxy-10,12-dimethoxy-5-phenyl-7-oxa-11-azatricyclo[6.4.0.0,dodeca-1(12),8,10-trien-6-yl]benzonitrile;EFT-226;UNII-2EWN8Z05CN;Zotatifin;2098191-54-7;Zotafin;AKOS040742848;BDBM50540861;Zotatifin [INN];Benzonitrile, 4-((5aR,6S,7S,8R,8aS)-7-((dimethylamino)methyl)-6,7,8,8a-tetrahydro-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-5ah-cyclopenta(4,5)furo(3,2-C)pyridin-5a-yl)-;MS-29059;EX-A4623;G17541;G17581;NSC818001;CHEMBL4303782;2098191-53-6;NSC-828584;Zotatifin (USAN/INN);4-((5aR,6S,7S,8R,8aS)-7-((Dimethylamino)methyl)-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-6,7,8,8a-tetrahydro-5ah-cyclopenta(4,5)furo(3,2-C)pyridin-5a-yl)benzonitrile;DA-79135;

标识符

InChIKey:
QYCXWOACFWMQFO-WZWZCULESA-N
Inchi:
1S/C28H29N3O5/c1-31(2)16-20-23(18-8-6-5-7-9-18)28(19-12-10-17(15-29)11-13-19)27(33,25(20)32)24-21(36-28)14-22(34-3)30-26(24)35-4/h5-14,20,23,25,32-33H,16H2,1-4H3/t20-,23-,25-,27+,28+/m1/s1
SMILES:
C(#N)C1=CC=C([C@]23[C@H](C4=CC=CC=C4)[C@@H](CN(C)C)[C@@H](O)[C@@]2(O)C2=C(O3)C=C(OC)N=C2OC)C=C1

rel-4-[(5aR,6S,7S,8R,8aS)-7-[(二甲胺)甲基]-6,7,8,8a-四氢-8,8a-二羟基-1,3-二甲氧基-6-苯基-5aH-环五[4,5]呋喃[3,2-c]吡啶-5a-基]-苯甲腈(2098191-54-7)物化性质

计算特性

  • 精确分子量 : 487.21072103g/mol
  • 氢键供体数量 : 2
  • 氢键受体数量 : 8
  • 可旋转化学键数量 : 6
  • 同位素质量 : 487.21072103g/mol
  • 重原子数量 : 36
  • 复杂度 : 819
  • 同位素原子数量 : 0
  • 确定原子立构中心数量 : 5
  • 不确定原子立构中心数量 : 0
  • 确定化学键立构中心数量 : 0
  • 不确定化学键立构中心数量 : 0
  • 共价键单元数量 : 1
  • 疏水参数计算参考值(XlogP) : 2.4
  • 拓扑分子极性表面积 : 108Ų

rel-4-[(5aR,6S,7S,8R,8aS)-7-[(二甲胺)甲基]-6,7,8,8a-四氢-8,8a-二羟基-1,3-二甲氧基-6-苯基-5aH-环五[4,5]呋喃[3,2-c]吡啶-5a-基]-苯甲腈(2098191-54-7)推荐厂家 更多厂家(3)

公司名称手机号/电话联系人QQ微信询单
MedChemExpress(MCE 中国) 13611715263
021-58955995
MCE生命科学试剂 2881321772
询单
上海源溪生物科技有限公司 13564518121李经理 1724405207 询单
上海阿拉丁生化科技股份有限公司 13167063860
13167063860
阿拉丁 3004013043
询单